Shore Capital Reiterates AstraZeneca PLC

Shore Capital reiterated a "Buy" recommendation for AstraZeneca (AZN) on November 6, 2025, setting an average one-year price target of $91.56, which suggests an 8.25% upside from its $84.58 closing price. This outlook is presented alongside a projected 9.73% decrease in annual revenue to $52,474MM and an expected non-GAAP EPS of $10.23. While fund sentiment appears bullish with a 0.60 put/call ratio and an increase in the number of institutional holders, total institutional shares decreased by 2.42% in the last quarter, with several major holders reducing their positions and portfolio allocations to AZN.

Analysis

Shore Capital reiterated a "Buy" recommendation for AstraZeneca (AZN) on November 6, 2025, setting an average one-year price target of $91.56, which implies an 8.25% upside from its last reported closing price of $84.58. This positive analyst outlook contrasts with the projected annual revenue of $52,474MM, which represents a notable 9.73% decrease, alongside a projected non-GAAP EPS of $10.23.

Institutional investor activity presents a mixed picture; while the number of funds holding AZN increased by 1.99% to 1,740 and the average portfolio weight dedicated to AZN rose by 6.10%, total institutional shares decreased by 2.42% to 637,486K shares over the last quarter. This suggests broader participation but reduced conviction in terms of aggregate share volume.

Several major institutional holders, including T. Rowe Associates and Wellington Management Group, significantly reduced their AZN shareholdings by 9.90% and 3.77% respectively, and decreased portfolio allocations by 20.46% and 13.55%. Despite this institutional selling, the put/call ratio of 0.60 indicates a bullish options market sentiment, creating a divergence between equity positioning and options market expectations.

Key Decisions for Investors

• Investors should scrutinize the discrepancy between Shore Capital's "Buy" rating and the projected 9.73% revenue decline, evaluating the underlying drivers for both.
• Monitor institutional share movements, particularly the aggregate decrease in total shares held and significant reductions by major holders, despite an increase in the number of funds.
• Consider the bullish put/call ratio in conjunction with the negative per-ticker sentiment for AZN, as these divergent signals suggest a complex risk-reward profile.